Obagi Announces Results of Three Clinical Studies
LONG BEACH, Calif.–(BUSINESS WIRE)–March 2, 2006–Obagi Medical Products, Inc. (Obagi) announced today that they will present three clinical posters on a novel Benzoyl Peroxide (BPO) formulation for the treatment of P. Acnes at the 64th annual American Association of Dermatology (AAD) meeting in San Francisco this week.
Three separate clinical trials demonstrate the unique properties of a new BPO technology that increases penetration to the infected follicle. These results were achieved through the application of Obagi’s Penetrating Therapeutics(TM) technologies to a BPO formulation. more …